Search

Displaying results 4551 - 4560 of 6076 in total
  1. Drug

    Cannabichromene

    go.drugbank.com/drugs/DB14735
    Investigational

    A natural product found in Cannabis sativa and Helichrysum species.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Dociparstat sodium

    go.drugbank.com/drugs/DB16481
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

  4. Drug

    Masofaniten

    go.drugbank.com/drugs/DB21580
    Investigational

    Masofaniten is under investigation in clinical trial NCT06312670 (Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer).

  5. Drug

    Bismuth subgallate

    go.drugbank.com/drugs/DB13909
    Approved

    Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. Possessing ...

  6. Drug

    Tilorone

    go.drugbank.com/drugs/DB17965
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

  8. Drug

    Gossypol

    go.drugbank.com/drugs/DB13044
    Investigational

    Gossypol has been used in trials studying the treatment of Non-small Cell Lung Cancer.

    Categories: Hormonal Contraceptives for Systemic Use
  9. Drug

    Fenpiprane

    go.drugbank.com/drugs/DB13439
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  10. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL).